

## ASX Announcement

### HER-Vaxx induced antibodies correlated with tumour reduction

---

**Sydney, Australia, 30 June 2023:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona.

**Abstract Title:** HERIZON: A Phase 2 study of HER-Vaxx (IMU-131), a HER-2-targeting peptide vaccine plus SOC chemotherapy in patients with HER-2+ advanced stomach Cancer – Correlation of the antibody responses and clinical outcome.

**Session Title:** Basic Gastric Cancer – Biomarkers and Translational Research.

**Session Number:** Poster Discussion D-8.

**Presentation Session:** 29 June 2023, 9:30 am – 5:40 pm CEST.

**Presenting Author:** Dr Joshua Tobias, Medical University of Vienna, Vienna, Austria.

Conclusions drawn from the study include;

- HER-Vaxx treatment produced robust anti-HER-2-IgG\* and IgG1 antibody responses ( $p < 0.001$ ).
- HER-Vaxx-based vaccination of patients with HER-2 overexpressing gastric/gastro-esophageal junction cancer (GC) induced anti-HER-2-IgG and IgG1 subclass antibody responses ( $p < 0.001$ ).
- HER-Vaxx induced antibodies correlated with tumour reduction ( $p = 0.001$ )
- Compared to chemotherapy alone, the vaccination resulted in a statistically significant overall survival benefit.
- The present data further validate the proof of concept for a first-in-class B-cell immunotherapy based on HER-2/neu peptides.

\* IgG – Immunoglobulin G is a type of antibody. Representing approximately 75% of serum antibodies in humans, IgG is the most common type of antibody found in blood circulation.



For 25 years, the World Congress on Gastrointestinal Cancer has been the foundation for sharing the most advanced research and innovations impacting the field of Gastrointestinal Cancer.

As the largest global gathering in the field, the Congress brings together leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe to share pioneering research, approaches, and best practices in treating patients with cancers of the gastrointestinal tract.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
info@imugene.com

**Investor Enquiries**  
shareholderenquiries@imugene.com

**Media Enquiries**  
Matt Wright  
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited  
View us on YouTube @Imugene Limited

### **About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with



standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer*